# EDGAR Filing Document

**Accession Number:** 0001635088
**File Stem:** 0001140361-25-034711
**Filing Date:** 2025-9
**Character Count:** 6862
**Document Hash:** 94e9ad7de50a503b59979bedd9095c34
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-034711.hdr.sgml**: 20250911

**ACCESSION NUMBER**: 0001140361-25-034711

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250910

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250911

**DATE AS OF CHANGE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Roivant Sciences Ltd.
- **CENTRAL INDEX KEY:** 0001635088
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981173944
- **STATE OF INCORPORATION:** D0
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40782
- **FILM NUMBER:** 251309191

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB
- **BUSINESS PHONE:** 441-295-5950

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 7TH FLOOR, 50 BROADWAY
- **CITY:** LONDON
- **NON US STATE TERRITORY:** UNITED KINGDOM
- **PROVINCE COUNTRY:** X0
- **ZIP:** SW1H 0DB

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the

#### Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): September 10, 2025

## Roivant Sciences Ltd.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Bermuda**  | 001-40782 | 98-1173944<br>|
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)**  | **(I.R.S. Employer Identification No.)** |

---

#### 7th Floor

#### 50 Broadway

#### London SW1H 0DB

#### United Kingdom

#### (Address of principal executive offices, and Zip Code)

#### +44 207 400-3347

#### Registrant's Telephone Number, Incl uding Area Code

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Shares, $0.0000000341740141 per share**<br>| **ROIV**  | **The Nasdaq Global Select Market**  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On September 10, 2025, Roivant Sciences Ltd. (the "Company") held its 2025 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon three proposals as described in more detail in the Company's Proxy Statement.

Of 682,519,374 common shares outstanding and entitled to vote as of the close of business on the record date for the meeting, July 17, 2025, the holders of record of 628,673,675 common shares were present at the meeting either in person or by proxy. All proposals on the agenda were approved by the shareholders. Below are the final voting results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their
 successors are duly elected and qualified, or until such director's earlier death, resignation or removal. Election of each director required approval by a plurality of the votes cast.

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Matthew Gline | 430,013,727 | 154,432,135 | 44,227,813 |
| Keith Manchester | 412,869,513 | 171,576,349 | 44,227,813 |
| Melissa Epperly | 429,542,705 | 154,903,157 | 44,227,813 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for
 statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2026. Ratification required a simple majority of the votes cast.

---

| | |
|:---|:---|
| **For** | 628,068,956 |
| **Against** | 479,264 |
| **Abstain** | 125,455 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures.

---

| | |
|:---|:---|
| **For** | 316,651,402 |
| **Against** | 203,244,184 |
| **Abstain** | 64,550,276 |
| **Broker Non-Vote** | 44,227,813 |

---

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

<u> Exhibit No. </u> <u> Description </u> <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ROIVANT SCIENCES LTD.** | **ROIVANT SCIENCES LTD.** |
| Date: September 11, 2025 | By:  | /s/ Keyur Parekh |
|  |  | Name: Keyur Parekh |
|  |  | Title: Authorized Signatory |

---

------